Hologic acquires Spain’s Reveal Genomics to expand breast cancer genomic testing

Hologic, a medical‑technology company, announced it will acquire precision‑oncology firm Reveal Genomics, based in Spain.

Reveal Genomics develops advanced genomic diagnostic tests, notably the HER2DX assay that aims to guide therapy choices for patients with HER2‑positive breast cancer. Its portfolio complements Hologic’s Breast Cancer Index test, which is used to inform extended endocrine therapy decisions in hormone‑receptor‑positive early‑stage disease.

The acquisition follows Hologic’s 2025 sale to Blackstone and TPG valued at more than $18.3 billion and is intended to broaden the company’s oncology diagnostics suite, offering a wider range of genomic tests to support personalized treatment for more women with breast cancer.

Breast cancer incidence continues to rise, especially among women under 50, underscoring the relevance of expanded diagnostic options.